[1] Bryson, H. M., & Faulds, D. (1997). Cisatracurium besilate. a review of its pharmacology and clinical potential in anaesthetic practice. Drugs, 53(5), 848-866.
[2] Liu, X. , Kruger, P. S. , Weiss, M. , & Roberts, M. S. . (2012). The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. British Journal of Clinical Pharmacology, 73(5), 741-749.
[3] Welch, R. M. , Brown, A. , Ravitch, J. , & Dahl, R. . (1995). The in vitro degradation of cisatracurium, the r, cis-r′-isomer of atracurium, in human and rat plasma. Clinical Pharmacology & Therapeutics, 58(2), 132-142.
[4] Welch, R. M. , Brown, A. , & Dahl, R. . (1994). The degradation and metabolism of 51w89, the r,cis-r1,cis isomer of atracurium, in human and rat plasma. Anesthesiology, 81(SUPPLEMENT), A1092.
[5] Akinseye, O. A. , Pathak, A. , & Ibebuogu, U. N. . (2017). Aortic valve regurgitation: a comprehensive review. Current Problems in Cardiology.
[6] Goldbarg, S. H. , & Halperin, J. L. . (2008). Aortic regurgitation: disease progression and management. Nature Clinical Practice Cardiovascular Medicine, 5(5), 269-279.
[7] Yeung, A. C. , Plappert, T. , & Sutton, M. G. S. J. . (1992). Calculation of aortic regurgitation orifice area by doppler echocardiography: an application of the continuity equation. British Heart Journal, 68(2), 236.
[8] Mentias, A. , Feng, K. , Alashi, A. , Rodriguez, L. L. , Gillinov, A. M. , & Johnston, D. R. , et al. (2016). Long-term outcomes in patients with?aortic regurgitation and preserved?left ventricular ejection fraction. Journal of the American College of Cardiology, 68(20), 2144-2153.
[9] Nkomo, V. T. . (2003). Indications for surgery for aortic regurgitation. Current Cardiology Reports, 5(2), 105-109.
[10] Vanderweide, L. , Abdel-Rasoul, M. , & Gerlach, A. T. . (2017). The incidence of hypotension with continuous infusion atracurium compared to cisatracurium in the intensive care unit. International Journal of Critical Illness & Injury Science, 7(2), 113-118.
[11] Wu, Z. , Wang, S. , Peng, X. , Lu, C. , Ye, X. , & Wu, B. . (2015). Altered cisatracurium pharmacokinetics and pharmacodynamics in patients with congenital heart defects. Drug Metabolism and Disposition, 44(1), 75-82.
[12] Liu, J. , Lu, C. , Zou, Q. , Wang, S. , & Peng, X. . (2016). Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anesthetic induction period. British Journal of Clinical Pharmacology.
[13] Kisor, D. D. F. , & Schmith, V. D. . (1999). Clinical pharmacokinetics of cisatracurium besilate. Clinical Pharmacokinetics, 36(1), 27-40.
[14] Kim, J. H. , Lee, Y. C. , Lee, S. I. , Park, S. Y. , Choi, S. R. , & Lee, J. H. , et al. (2016). Effective doses of cisatracurium in the adult and the elderly. Korean Journal of Anesthesiology, 69(5), 453-459.
[15] Bergeron, L. , Bevan, D. R. , Berrill, A. , Kahwaji, R. , & Varin, F. . (2001). Concentration–effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology, 95(2), 314-323.
[15] Mellinghoff, H. , & Diefenbach, C. . (1997). [the clinical pharmacology of cisatracurium]. Der Anaesthesist, 46(6), 481.